Steven Verhoeven, previously Chief Operating Officer of Velsera and Chief Executive Officer of UgenTec, will join Aspect Analytics as Executive Chairman. Verhoeven will be responsible for continuing the exponential growth of Aspect Analytics, exploring new markets & maintaining investor relations.

Aspect Analytics offers unique capabilities in analyzing spatial multi-omics data, enabling breakthrough discoveries in pharmaceutical R&D through improved understanding of the tissue microenvironment. Aspect Analytics is growing rapidly, supporting an increasing number of pharmaceutical R&D teams as well as international spatial multi-omics consortia, such as the Horizon GLIOMATCH and a Michael J Fox Foundation-funded project investigating changes in lipid metabolism related to Parkinson’s Disease.

Steven’s experience lies in leading fast growing teams and scaling up organizations from a customer-centric perspective. As CEO, Verhoeven led UgenTec’s rapid growth culminating in the acquisition by Summa Equity and incorporation into Velsera where he was overseeing the science and customer success organization. At Agilent Technologies, Verhoeven was responsible for strategy and success of a suite of software products in clinical and translational genomics. Verhoeven previously also led operations at the Belgian genomics software company Cartagenia as COO and built out an international delivery organization as VP of Professional Services for BAE Systems Detica.

“I’m excited and deeply appreciative to become part of the Aspect Analytics team.” says Steven Verhoeven, “Their unique ability to integrate data across multiple spatial biology assays and perform AI supported data analysis, is enabling unprecedented insight into drug targets and mechanisms.”

“We founded the company in 2018 with a clear vision: to deliver cutting-edge digital spatial biology solutions that equip key players in life sciences R&D with actionable insights into tissue and disease biology,” said Marc Claesen, CEO at Aspect Analytics. “Steven’s proven track record in scaling life science software companies will be instrumental in helping us achieve that vision. We’re thrilled to bolster our executive team with someone of his caliber, especially as we continue to expand internationally.”

‍